Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Marketability of a technology-based intervention to increase HPV vaccination.

Award Number: R44DP006291
ORGANIZATION: NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION & HEALTH PROMOTION
OPDIV: CDC
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2016
PERIOD OF PERFORMANCE END DATE: 09/29/2018

Group Awards By:

View Award Description

Marketability of a technology-based intervention to increase HPV vaccination. - The purpose of this Phase II research project is to evaluate and market an innovative health message intervention to increase uptake of the human papillomavirus (HPV) vaccine and reduce women’s cervical cancer risk through partnership with Planned Parenthood. The overall aim is to reach a broad population through Planned Parenthood, the nation’s leading sexual and reproductive health care center, especially among low socioeconomic status (SES) and historically underserved populations. Despite an overall increase in vaccination and reduction in HPV-related infections in younger populations targeted by previous health promotion efforts, young adult women who are recommended for vaccination demonstrate much lower vaccination rates and higher rates of infection. In a recent Phase I grant, we developed and demonstrated the usability and feasibility of an innovative, culturally-grounded, technology-based narrative intervention that delivers decision narratives in the form of videos via a health kiosk, an underutilized communication strategy for reaching less involved audiences. This brief, low-cost, easily implementable intervention doubled the uptake of the vaccine in a separate pilot study. The proposed Phase II project will: (1) Complete development of the intervention, (2) Evaluate its effectiveness through a randomized clinical trial, and (3) Prepare the product for the market. To accomplish these aims, we will develop the intervention for implementation in waiting rooms as part of check-in procedures and exam rooms as part of intake. Our pilot research suggests these are both viable implementation strategies. Development includes programing and installing tablets to accomplish these tasks (Aim 1). We will then conduct the evaluation study in six Planned Parenthood clinics in southeastern Pennsylvania (Aim 2). In the waiting room condition, women will complete check-in via a tablet and that information used to identify and recruit eligible volunteers (unvaccinated women aged 18-26). In the exam room condition the intervention will be viewed on a tablet as part of the intake procedure, facilitated by a nurse or other designated clinic staff. Eligible women will be consented, complete a pretest, and then randomized to view the brief intervention or attention control messages via the tablet. After viewing the messages, they will complete a short posttest. Participants will receive follow up texts/emails reminding them to vaccinate, as well as texts/emails with links that allow them to complete posttest surveys at 3- and 9 months. Finally, we will prepare the intervention for the market that includes not only Planned Parenthood but other clinics that are currently served by the project partners as well as the broader market for HPV vaccination (Aim 3). In summary, the proposed communication strategy has wide reaching implications not only for reducing cancer risk, but more broadly for designing brief and easily implemented prevention messages across many domains of public health. The research will also close the health disparities gap in minority, underserved young adult women’s access to preventive health care.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $794,930 )
2017	2017	REAL PREVENTION LLC	130 PEARL BROOK DR	CLIFTON	NJ	07013	PASSAIC	USA	Food and Drug Administration Research	002	3	8/18/2017	NON-COMPETING CONTINUATION	$794,930
2017	2016	REAL PREVENTION LLC	130 PEARL BROOK DR	CLIFTON	NJ	07013	PASSAIC	USA	Food and Drug Administration Research	001	2	2/16/2017	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2017	2016	REAL PREVENTION LLC	130 PEARL BROOK DR	CLIFTON	NJ	07013	PASSAIC	USA	Food and Drug Administration Research	000	2	11/16/2016	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $794,930

Issue Date FY: 2016 ( Subtotal = $500,000 )
2016	2016	REAL PREVENTION LLC	765 LONG HILL RD	GILLETTE	NJ	07933	MORRIS	USA	Food and Drug Administration Research	000	2	8/17/2016	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$500,000
														Subtotal = $500,000

Grand Total All Awards = $1,294,930

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Marketability of a technology-based intervention to increase HPV vaccination.

Award Number: R44DP006291

ORGANIZATION: NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION & HEALTH PROMOTION

OPDIV: CDC

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2016

PERIOD OF PERFORMANCE END DATE: 09/29/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer